POINT Biopharma Global Inc.
PNTDelisted Dec 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001811764
POINT Biopharma Global Inc. was delisted on Dec 27, 2023; its insiders filed their last Form 4 on Dec 27, 2023; 126 institutions reported holding it in 13F filings for Q3 2023, worth $411.0M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 126
- Q3 2023, −4 vs. previous quarter
- 13F value
- $411.0M
- Reported value at the end of Q3 2023
- Superinvestors holding
- 0
- At the end of Q3 2023
Superinvestors holding PNT, Q3 2023
No superinvestor reported holding PNT at the end of Q3 2023.
Latest insider trades
Open-market purchases and sales by POINT Biopharma Global Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 20, 2023 (view filing)6:09 PM ET | Dec 18 | 2 days | Biotechnology Value Fund L P and 9 othersOther: Former 10% Owner | SSaleCommon Stock, $0.0001 par value | −17.2M | $12.45 | −$213.7M | −100.0%0 after | 3 lots |
| Nov 30, 2022 (view filing) | Nov 29 | 1 day | McCann Joe A.Chief Executive Officer | PPurchase | +2.16K | $6.64 | +$14.3K | +0.1%3.62M after | |
| Nov 28, 2022 (view filing) | Nov 25 | 3 days | Hogue Gerald L.Director | PPurchase | +3.66K | $6.82 | +$25.0K | New position3.66K after | |
| Nov 28, 2022 (view filing) | Nov 23 | 5 days | Lubner David CharlesDirector | PPurchase | +3.60K | $6.85 | +$24.7K | New position3.60K after | |
| Nov 28, 2022 (view filing) | Nov 28 | Same day | Malik RajeshDirector | PPurchase | +3.70K | $6.66 | +$24.6K | New position3.70K after | |
| Nov 23, 2022 (view filing) | Nov 21 | 2 days | Margolin YaelDirector | PPurchase | +1.71K | $6.56 | +$11.2K | New position1.71K after | |
| Nov 21, 2022 (view filing) | Nov 18 | 3 days | Goodman Jonathan R.Director | PPurchase | +6.00K | $6.33 | +$38.0K | +16.7%41.9K after | |
| Nov 21, 2022 (view filing) | Nov 17-18 | 4 days | Silber Allan CExecutive Chairman | PPurchase | +50.0K | $6.22 | +$311.2K | +1.2%4.27M after | 2 lots |
| May 26, 2022 (view filing) | May 25 | 1 day | Fleshner Neil E.Chief Medical Officer | SSale | −564.2K | $7.51 | −$4.24M | −15.7%3.02M after |
Top 10 13F holders, Q3 2023
The largest institutional positions in POINT Biopharma Global Inc. at the end of Q3 2023; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 10,563,748 | $70.5M | 1.90% | 00.0% | Unchanged |
| BlackRock Inc. | 6,635,892 | $44.3M | 0.00% | +285,792+4.5% | Added |
| Vanguard Group Inc | 4,667,786 | $31.1M | 0.00% | +212,433+4.8% | Added |
| State Street Corp | 3,527,235 | $23.5M | 0.00% | +131,083+3.9% | Added |
| Great Point Partners LLC | 2,909,960 | $19.4M | 3.65% | −90,040−3.0% | Reduced |
| Deep Track Capital, LP | 2,781,565 | $18.6M | 0.72% | 00.0% | Unchanged |
| Boxer Capital, LLC | 2,500,000 | $16.7M | 0.89% | 00.0% | Unchanged |
| Bellevue Group AG | 2,351,160 | $15.7M | 0.25% | +1,094,963+87.2% | Added |
| Citadel Advisors LLC | 2,157,166 | $14.4M | 0.02% | −297,807−12.1% | Reduced |
| Geode Capital Management, LLC | 1,900,074 | $12.7M | 0.00% | +174,687+10.1% | Added |